Engineering cancer cells is a promising immunotherapy to promote antitumor immunity. To make this happen, Creative Biolabs specializes in genetic designs and cell engineering to provide genetically modified colorectal cancer cell lines with the highest standards.

Engineering Colorectal Cancer Cell for Cancer Therapy

Modulation of the immune system for the treatment of cancer has been tested extensively in oncology. The clinical use of genetically modified tumor cells as therapeutic cancer vaccines has the potential advantages to induce potent antitumor immune responses. The use of cytokine gene-transfected tumor cells as a modality for cancer therapy has been widely studied in many cancer treatments, such as melanoma, colorectal cancer (CRC), and renal cancer. Combining potentially synergistic cytokines to modify tumor cell vaccine can activate immune cells, and improve immunogenicity and tumor-specific immunity.

Fig.1 Cytokine networks in the pathogenesis of CRC. (Mager, et al., 2021)

Colorectal Cancer Facts

• CRC is the third most common cancer worldwide.
• CRC is the third leading cause of cancer death in men and the third leading cause of cancer death in women.
• The 5-year relative survival rate of CRC is 65%. However, survival rates for CRC can vary based on several factors.
• It is estimated that 52,580 deaths (28,400 men and 24,180 women) from this disease occur in the United States in 2022.

Fig.2 The estimated CRC incident cases and deaths in 2020 and projections for 2040. (Xi & Xu, 2021)

Studies Performed with Engineered Colorectal Cancer Cells

CRC is the third most common cancer worldwide and the second most common cause of cancer-related mortality. It has been reported that CRC cell line CT26 expressing granulocyte macrophage-colony-stimulating factor (GM-CSF), interferon (IFN-γ), or monocyte chemotactic protein1 (MCP-1), effectively established antitumor immunity to prevent and eliminate the tumor.

Engineering Colorectal Cancer Cell Service

• Engineering Various CRC Cell Lines

CRC is a heterogeneous disease, with subtypes that are driven by different types of genomic alterations. Classical CRC somatic mutations genes include TP53, APC, KRAS, FBXW7, PIK3CA, and SMAD4, which can promote the survival and proliferation of cancer cells. CRC cell lines have derived from different CRC subtypes and show different phonotypic and molecular properties in vivo and in vitro studies. Now, we have established a platform to engineer various CRC cell lines expressing cytokines, etc. for cancer therapy research. The CRC cell lines you can choose include but are not limited to:

• Engineering CRC Cells via Different Genetic Methods

The transduction of exogenous genes to target cells is typically achieved using viral transduction such as retrovirus, lentivirus, adenovirus, and adeno-associated virus, or non-viral delivery system. In addition, the advent of gene editing via the CRISPR system has enabled more precise genetic manipulation to optimize cell engineering and function.

• Different Cytokines Overexpression

Cytokines can modulate the inflammatory milieu in tumor tissues. We have developed engineered cancer cells overexpressing cytokine for stronger T-cell activation. The following are different cytokines you can choose to engineer.If you are interested in our services, please feel free to contact us to discuss your project.

References

1. Nagai, E.; et al. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunology, Immunotherapy. 1998, 47(2): 72-80.
2. Mager, L.F.; et al. Cytokine-induced modulation of colorectal cancer. Frontiers in oncology. 2016, 6: 96.
3. Xi, Y.; Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology. 2021, 14(10): 101174.

For Research Use Only | Not For Clinical Use